INT15744

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.64
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 12
Total Number 14
Disease Relevance 7.19
Pain Relevance 2.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (GYPA) molecular_function (GYPA) cellular_component (GYPA)
biological_process (GYPA)
Anatomy Link Frequency
liver 3
heart 2
coronary artery 1
pulmonary artery 1
GYPA (Homo sapiens)
Pain Link Frequency Relevance Heat
Bile 3 99.68 Very High Very High Very High
positron emission tomography 138 99.04 Very High Very High Very High
tolerance 5 98.92 Very High Very High Very High
diabetic neuropathy 33 98.32 Very High Very High Very High
Angina 19 97.88 Very High Very High Very High
imagery 69 97.48 Very High Very High Very High
Dopamine 234 94.96 High High
withdrawal 2 82.96 Quite High
headache 1 80.16 Quite High
depression 9 74.04 Quite High
Disease Link Frequency Relevance Heat
Liver Disease 36 99.88 Very High Very High Very High
Diabetes Mellitus 23 99.44 Very High Very High Very High
Coronary Artery Disease 8 99.16 Very High Very High Very High
Parkinsonian Disorders 117 98.68 Very High Very High Very High
Diabetic Neuropathy 34 98.32 Very High Very High Very High
Cv General 3 Under Development 10 97.88 Very High Very High Very High
Stable Angina Pectoris 4 94.96 High High
Neurological Disease 7 94.68 High High
Cirrhosis 3 94.40 High High
Aging 36 93.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This absence of a zero hour effect suggests that rebound does not occur during eccentric dosing with immediate-release IS-5-MN.
Localization (release) of IS-5-MN
1) Confidence 0.64 Published 1993 Journal Am. J. Cardiol. Section Abstract Doc Link 8213541 Disease Relevance 0.30 Pain Relevance 0.34
We conducted a controlled double-blind trial comparing the effects of isosorbide-5-mononitrate (IS-5-MN) 3 X 20 mg, sustained release IS-5-MN 50 mg once daily and sustained release nifedipine 3 X 20 mg in patients with documented coronary heart disease and transient ischaemic episodes. 20 patients were included, 15 finished the four-week study period.
Localization (release) of IS-5-MN in heart associated with coronary artery disease
2) Confidence 0.51 Published 1988 Journal Eur. Heart J. Section Abstract Doc Link 3409907 Disease Relevance 0.60 Pain Relevance 0.24
In a double-blind, randomized cross-over study the antianginal efficacy and tolerability of Elantan Long (50 mg sustained-release IS-5-MN) were compared with a 80-mg sustained-release (s.r.)
Localization (release) of IS-5-MN
3) Confidence 0.50 Published 1991 Journal Cardiology Section Abstract Doc Link 1760831 Disease Relevance 0.14 Pain Relevance 0.07
Sustained-release IS-5-MN in the treatment of coronary heart disease.
Localization (release) of IS-5-MN in heart associated with coronary artery disease
4) Confidence 0.50 Published 1991 Journal Cardiology Section Title Doc Link 1760831 Disease Relevance 0.41 Pain Relevance 0.23
To determine whether nitration was related to the decline of Mn-SOD activity in the SO group, Mn-SOD nitration was evaluated following immuno-precipitation of Mn-SOD.
Localization (precipitation) of Mn-SOD
5) Confidence 0.33 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2875392 Disease Relevance 0.15 Pain Relevance 0
Inefficient targeting of Mn-SOD may leave mitochondria inabequately defended against superoxide radicals.
Localization (targeting) of Mn-SOD
6) Confidence 0.32 Published 2001 Journal BMC Med Genet Section Body Doc Link PMC31388 Disease Relevance 0.89 Pain Relevance 0.09
This finding is likely because Mn is excreted in the bile, and in persons with chronic liver disease, the excretion of Mn is markedly impaired, with subsequent accumulation in the brain.
Localization (excretion) of Mn in liver associated with liver disease and bile
7) Confidence 0.22 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 1.49 Pain Relevance 0.10
Importantly, for patients with liver disease, the hyperintensive T1-weighted MRI signal in the basal ganglia is normalized after liver transplantation (Aggarwal et al. 2006) that corrects the impairment in Mn excretion.
Localization (excretion) of Mn in liver associated with liver disease and imagery
8) Confidence 0.22 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.64 Pain Relevance 0.47
This finding is likely because Mn is excreted in the bile, and in persons with chronic liver disease, the excretion of Mn is markedly impaired, with subsequent accumulation in the brain.
Localization (excreted) of Mn in liver associated with liver disease and bile
9) Confidence 0.19 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 1.39 Pain Relevance 0.10
Once-a-day therapy with a slow-release formulation of IS-5MN is used widely in Europe for 24-hour prophylaxis of angina pectoris.
Localization (release) of IS-5MN associated with angina
10) Confidence 0.02 Published 1987 Journal Am. J. Cardiol. Section Abstract Doc Link 3825935 Disease Relevance 0.39 Pain Relevance 0.35
Two hours after administration of 100 mg sustained-release IS-5-MN, mean resting pulmonary artery pressure (PAP), measured with a Swan-Ganz catheter, was reduced by 32% (p less than 0.001) and at submaximal exercise level (50 W, 3 min) by 37% (p less than 0.001).
Localization (release) of IS-5-MN in pulmonary artery
11) Confidence 0.01 Published 1991 Journal Cardiology Section Abstract Doc Link 1760835 Disease Relevance 0.26 Pain Relevance 0.21
At the end of 1 week of therapy with sustained-release IS-5-MN a slight, clinically irrelevant reduction of hemodynamic effect was recorded.
Localization (release) of IS-5-MN
12) Confidence 0.01 Published 1991 Journal Cardiology Section Abstract Doc Link 1760835 Disease Relevance 0.22 Pain Relevance 0.18
The possibility of maintaining preload reduction and enhancement of exercise tolerance during an interval treatment with 100 mg/day of slow-release isosorbide-5-mononitrate (IS-5-MN) was investigated in 12 patients (aged 57 +/- 5.0 years) with angiographically confirmed coronary artery disease and chronic stable angina pectoris.
Localization (release) of IS-5-MN in coronary artery associated with stable angina pectoris, angina, coronary artery disease and tolerance
13) Confidence 0.01 Published 1991 Journal Cardiology Section Abstract Doc Link 1760835 Disease Relevance 0.27 Pain Relevance 0.22
However, SDS-PAGE and Western blot analysis of lysates from cells transfected with wt or p.Glu252Lys A-domain revealed that non-reduced samples contained a mixture of both forms of A-domain in approximately equal quantities (Fig. 2B; lanes 2 and 3), which is characteristic of a cell expressing high levels of recombinant protein that is actively being folded and secreted.
Localization (secreted) of recombinant protein
14) Confidence 0.01 Published 2005 Journal Human Mutation Section Body Doc Link PMC2726956 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox